Treatment options for nonalcoholic fatty liver disease: a double-blinded randomized placebo-controlled trial
Discussion and conclusion
This randomized double-blinded placebo-controlled clinical trial suggested a significant benefit of silymarin, pioglitazone, and vitamin E in improving liver aminotransferases in patients with NAFLD after only 3 months, without exerting any specific side effects.
Source: European Journal of Gastroenterology and Hepatology - Category: Gastroenterology Tags: Original Articles: Hepatology Source Type: research
More News: Actos | Cardiology | Cardiovascular | Clinical Trials | Fatty Liver Disease (FLD) | Fortamet | Gastroenterology | Heart | Liver | Liver Disease | Liver Transplant | Metformin | Non-alcoholic Fatty Liver Diseases (NAFLD) | Statistics | Transplants | Urology & Nephrology | Vitamin E | Vitamins | Women